The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary

Multiple Sclerosis Journal

Volumn 21, Issue 4, 2015, Pages 374-375

  Hutchinson, Michael ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Atrophy; citicoline; MRI; Multiple sclerosis; neuroprotection; remyelination

Indexed keywords

CITICOLINE; NEUROFILAMENT PROTEIN; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

BRAIN ATROPHY; BRAIN SIZE; DEGENERATIVE DISEASE; GENE LOCUS; HUMAN; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; NOTE; REMYELINIZATION; DISABILITY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATION; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ANIMAL; DEMYELINATING DISEASE; PATHOLOGY;

ANIMALS; CYTIDINE DIPHOSPHATE CHOLINE; DEMYELINATING DISEASES; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 84953381304     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515573096     Document Type: Note

References (12)

1. Geurts JJ, Calabrese M, Fisher E, et al. Measurement and clinical effect of gray matter pathology in multiple sclerosis. Lancet Neurol. 2012 ; 11: 1082-1092
2. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
3. Skripuletz T, Manzel A, Gropengießer K, et al. Pivotal role of choline metabolites in remyelination. Brain. 2014 ;:
4. Knippenberg S, Skripuletz T, Rath KJ, et al. CDP-choline is not protective in the SOD1-G93A mouse model of ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013 ; 14: 284-290
5. Overgaard K. The effects of citicoline on acute ischemic stroke: A review. Stroke Cerebrovasc Dis. 2014 ; 23: 1764-1769
6. Qian K, Gu Y, Zhao Y, et al. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem Res. 2014 ; 39: 1206-1218
7. Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014 ; 28: 185-193
8. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet. 2014 ; 383: 2213-2221
9. Anderson VM, Bartlett JW, Fox NC, et al. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J Neurol. 2007 ; 254: 1588-1594
10. Nakamura K, Guizard N, Fonov VS, et al. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin. 2013 ; 4: 10-17
11. Salzer J, Svenningsson A, Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 ; 16: 287-292
12. Trentini A, Comabella M, Tintoré M, et al. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol. 2014 ; 261: 2338-2343